No interaction studies have been done.<unk>  and interleukin 17 are not known to interact with cytochrome P450 (CYP) liver enzymes. Since inflammation suppresses CYP activity, it is theorized that<unk>  could neutralize this effect and lower blood plasma concentrations of drugs that are metabolized by CYP enzymes, such as warfarin.
Ixekizumab
Caplacizumab
Satralizumab
Risankizumab
Brolucizumab
Bimekizumab
Tocilizumab
Etaracizumab